Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164943
Title: | Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response |
Author: | Iglesias, Pablo Ribero, Simone Barreiro Capurro, Alicia Podlipnik, Sebastian Carrera Álvarez, Cristina Malvehy, J. (Josep) Puig i Sardà, Susana |
Keywords: | Càncer de pell Vitiligen Melanoma Skin cancer Vitiligo Melanoma |
Issue Date: | 1-Feb-2019 |
Publisher: | Society for the Publication of Acta Dermato-Venereologica |
Abstract: | Talimogene laherparepvec (T-VEC) (Imlygic, Amgen) is the first oncolytic virus approved for use in therapy for metastatic melanoma. T-VEC provides a treatment option for patients with limited metastatic disease. T-VEC is a genetically modified, live, attenuated herpes simplex virus type 1 designed to replicate in tumour cells and promote an enhanced anti-tumour response (1) T-VEC is administered by injection into cutaneous, subcutaneous or nodal lesions, which are visible and/or palpable and/ or visualized by ultrasonography (2). Other local management options have been used to control metastatic disease in stage IIIB, but almost all have shown only a local effect and rapid disease relapse (3, 4). With T-VEC, responses occurred in injected and uninjected lesions, including a greater than 50% decrease in size in 15% of uninjected visceral lesions. The appearance of vitiligo has been described as an adverse event after administration of immune checkpoint inhibitors (5, 6). It has been reported as a marker of activity of the drug and long-term results, inducing clinicians to use it as a predictor of drug response (7). A T-VEC phase II study has reported 85% adverse events, all of which were grade 1 or 2. The appearance of vitiligo has been described in 3 patients out of 50 (8), although no details regarding duration and appearance have been reported. |
Note: | Reproducció del document publicat a: https://doi.org/10.2340/00015555-3061 |
It is part of: | Acta Dermato-Venereologica, 2019, vol. 99, num. 2, p. 232-233 |
URI: | http://hdl.handle.net/2445/164943 |
Related resource: | https://doi.org/10.2340/00015555-3061 |
ISSN: | 0001-5555 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
688464.pdf | 713.41 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.